Dr. Demetria C. Brown, PSY.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 11923 Centre St Ste A9, Chester, VA 23831 Phone: 804-861-6616 |
Dr. Sean Martin Goodwin Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 11601 Iron Bridge Rd Ste 201, Chester, VA 23831 Phone: 888-852-1988 |
Dr. Penny L. Sprecher, PH.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 12801 Iron Bridge Rd, Suite 400, Chester, VA 23831 Phone: 804-768-0295 Fax: 804-717-5269 |
Stephanie Lisa Montes Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 11800 Chester Village Dr Ste A, Chester, VA 23831 Phone: 914-498-1211 Fax: 804-715-4789 |
News Archive
Clinician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center are suggesting an immediate and important change to guidelines used in the care of patients with traumatic brain injury (TBI). The researchers say that following TBI, patients should be given nutritional supplementation through a gastric feeding tube as soon as possible, which they say can improve their chances of survival by as much as four-fold.
Springer and the British Society for Immunology (BSI) have entered into an agreement to publish six books per year, to be included in Springer's long-running book series, Advances in Experimental Medicine and Biology.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the release of NeuroApps: MRI Atlas of Human White Matter, the first in a new series of apps created for the iPad.
Sermo (http://www.sermo.com), the world's largest online physician's community, today announced a new Sermo Event(TM) Report assessing physician perception of FDA's "refuse to file" (RTF) letter on EMD Serono's Cladribine tablets and its potential impact, if any, on Novartis' oral MS agent in development; Fingolimod. Cladribine is expected to be one of the first oral agents to be approved for the treatment of relapsing and remitting multiple sclerosis.
› Verified 9 days ago